Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
40
PYPD Quote, Financials, Valuation and Earnings
Last price:
$4.40
Seasonality move
:
-12.3%
Day range:
$4.33 - $4.42
52-week range:
$2.30 - $5.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.65x
Volume:
54.3K
Avg. volume:
54.1K
1-year change:
61.99%
Market cap:
$84M
Revenue:
--
EPS (TTM):
-$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PYPD
PolyPid Ltd.
|
-- | -$0.40 | -- | -38.41% | $12.25 |
|
BLRX
BioLineRx Ltd.
|
$357K | -$0.32 | 35.2% | -49.07% | $20.33 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$1.2M | -$0.08 | -46.52% | -2.83% | $5.80 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.65 | 316.67% | -79.86% | $12.00 |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PYPD
PolyPid Ltd.
|
$4.39 | $12.25 | $84M | -- | $0.00 | 0% | -- |
|
BLRX
BioLineRx Ltd.
|
$2.21 | $20.33 | $10M | -- | $0.00 | 0% | 7.60x |
|
CANF
Can-Fite BioPharma Ltd.
|
$3.07 | $2.50 | $4.1M | -- | $0.00 | 0% | 7.14x |
|
CGEN
Compugen Ltd.
|
$2.26 | $5.80 | $220M | 6.30x | $0.00 | 0% | 2.99x |
|
PLUR
Pluri, Inc.
|
$3.32 | $12.00 | $33.4M | -- | $0.00 | 0% | 20.28x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$2.43 | -- | $5.7M | -- | $0.00 | 0% | 34.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PYPD
PolyPid Ltd.
|
20.31% | 0.659 | 3.54% | 1.70x |
|
BLRX
BioLineRx Ltd.
|
35.81% | 3.203 | 59% | 1.73x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 2.389 | -- | -- |
|
CGEN
Compugen Ltd.
|
2.8% | -0.650 | 2.05% | 6.45x |
|
PLUR
Pluri, Inc.
|
172.93% | -0.001 | 98.32% | 0.40x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | 0.921 | 1.28% | 0.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PYPD
PolyPid Ltd.
|
-$1.5M | -$8.5M | -192.32% | -313% | -- | -$8.5M |
|
BLRX
BioLineRx Ltd.
|
$91.6K | -$3.4M | -6.72% | -11.07% | -1745.49% | -$3.3M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$63.8M | $56M | 54.64% | 57.22% | 83.23% | -- |
|
PLUR
Pluri, Inc.
|
-$43K | -$6.5M | -93.31% | -5662.45% | -3285.86% | -$5.7M |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
PolyPid Ltd. vs. Competitors
-
Which has Higher Returns PYPD or BLRX?
BioLineRx Ltd. has a net margin of -- compared to PolyPid Ltd.'s net margin of -1152.66%. PolyPid Ltd.'s return on equity of -313% beat BioLineRx Ltd.'s return on equity of -11.07%.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.41 $13.8M BLRXBioLineRx Ltd.46.93% -$0.32 $33.5M -
What do Analysts Say About PYPD or BLRX?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 179.04%. On the other hand BioLineRx Ltd. has an analysts' consensus of $20.33 which suggests that it could grow by 820.06%. Given that BioLineRx Ltd. has higher upside potential than PolyPid Ltd., analysts believe BioLineRx Ltd. is more attractive than PolyPid Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 BLRXBioLineRx Ltd.2 0 0 -
Is PYPD or BLRX More Risky?
PolyPid Ltd. has a beta of 1.452, which suggesting that the stock is 45.189% more volatile than S&P 500. In comparison BioLineRx Ltd. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.372%.
-
Which is a Better Dividend Stock PYPD or BLRX?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLineRx Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. BioLineRx Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or BLRX?
PolyPid Ltd. quarterly revenues are --, which are smaller than BioLineRx Ltd. quarterly revenues of $195.2K. PolyPid Ltd.'s net income of -$8.5M is lower than BioLineRx Ltd.'s net income of -$2.3M. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while BioLineRx Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus 7.60x for BioLineRx Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$8.5M BLRXBioLineRx Ltd.7.60x -- $195.2K -$2.3M
-
Which has Higher Returns PYPD or CANF?
Can-Fite BioPharma Ltd. has a net margin of -- compared to PolyPid Ltd.'s net margin of --. PolyPid Ltd.'s return on equity of -313% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.41 $13.8M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About PYPD or CANF?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 179.04%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1528.67%. Given that Can-Fite BioPharma Ltd. has higher upside potential than PolyPid Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than PolyPid Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is PYPD or CANF More Risky?
PolyPid Ltd. has a beta of 1.452, which suggesting that the stock is 45.189% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 1.063, suggesting its more volatile than the S&P 500 by 6.323%.
-
Which is a Better Dividend Stock PYPD or CANF?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or CANF?
PolyPid Ltd. quarterly revenues are --, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. PolyPid Ltd.'s net income of -$8.5M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus 7.14x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$8.5M CANFCan-Fite BioPharma Ltd.7.14x -- -- --
-
Which has Higher Returns PYPD or CGEN?
Compugen Ltd. has a net margin of -- compared to PolyPid Ltd.'s net margin of 84.43%. PolyPid Ltd.'s return on equity of -313% beat Compugen Ltd.'s return on equity of 57.22%.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.41 $13.8M CGENCompugen Ltd.94.75% $0.60 $105.7M -
What do Analysts Say About PYPD or CGEN?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 179.04%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 156.64%. Given that PolyPid Ltd. has higher upside potential than Compugen Ltd., analysts believe PolyPid Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 CGENCompugen Ltd.5 0 0 -
Is PYPD or CGEN More Risky?
PolyPid Ltd. has a beta of 1.452, which suggesting that the stock is 45.189% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.766, suggesting its more volatile than the S&P 500 by 176.625%.
-
Which is a Better Dividend Stock PYPD or CGEN?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or CGEN?
PolyPid Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $67.3M. PolyPid Ltd.'s net income of -$8.5M is lower than Compugen Ltd.'s net income of $56.8M. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 6.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus 2.99x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$8.5M CGENCompugen Ltd.2.99x 6.30x $67.3M $56.8M
-
Which has Higher Returns PYPD or PLUR?
Pluri, Inc. has a net margin of -- compared to PolyPid Ltd.'s net margin of -3470.71%. PolyPid Ltd.'s return on equity of -313% beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.41 $13.8M PLURPluri, Inc.-21.72% -$0.71 $25.4M -
What do Analysts Say About PYPD or PLUR?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 179.04%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 261.45%. Given that Pluri, Inc. has higher upside potential than PolyPid Ltd., analysts believe Pluri, Inc. is more attractive than PolyPid Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 PLURPluri, Inc.1 0 0 -
Is PYPD or PLUR More Risky?
PolyPid Ltd. has a beta of 1.452, which suggesting that the stock is 45.189% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.767%.
-
Which is a Better Dividend Stock PYPD or PLUR?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or PLUR?
PolyPid Ltd. quarterly revenues are --, which are smaller than Pluri, Inc. quarterly revenues of $198K. PolyPid Ltd.'s net income of -$8.5M is lower than Pluri, Inc.'s net income of -$6.9M. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus 20.28x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$8.5M PLURPluri, Inc.20.28x -- $198K -$6.9M
-
Which has Higher Returns PYPD or XTLB?
XTL Biopharmaceuticals Ltd. has a net margin of -- compared to PolyPid Ltd.'s net margin of -341.36%. PolyPid Ltd.'s return on equity of -313% beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.41 $13.8M XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M -
What do Analysts Say About PYPD or XTLB?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 179.04%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 5048.45%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than PolyPid Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than PolyPid Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 XTLBXTL Biopharmaceuticals Ltd.0 0 0 -
Is PYPD or XTLB More Risky?
PolyPid Ltd. has a beta of 1.452, which suggesting that the stock is 45.189% more volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.270, suggesting its more volatile than the S&P 500 by 27.027%.
-
Which is a Better Dividend Stock PYPD or XTLB?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or XTLB?
PolyPid Ltd. quarterly revenues are --, which are smaller than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. PolyPid Ltd.'s net income of -$8.5M is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus 34.33x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$8.5M XTLBXTL Biopharmaceuticals Ltd.34.33x -- $162K -$553K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
